| Autor: |
Soike, K., Huang, J.-L., Tu, J.-I., Stouffer, B., Mitroka, J. G., Swerdel, M., Olsen, S., Bonner, D. P., Tuomari, A. V., Field, A. K. |
| Zdroj: |
The Journal of Infectious Diseases; April 1992, Vol. 165 Issue: 4 p732-732, 1p |
| Abstrakt: |
BV-araU (1-β-D-arabinofuranosyl-E-5-[2-bromovinyl]uracil) has potent antiviral activity against varicella zoster virus in cell culture and is undergoing clinical evaluation. In the present study, pharmacokinetic parameters and the efficacy of BV-araU against infection with simian varicella virus (SVV) were evaluated in African green monkeys. Pharmacokinetic parameters were determined by analysis of the BV-araD content of sera obtained after oral and intravenous administration to normal monkeys. Peak serum concentrations showed dose proportionality, with the 0.1 mg/kg dose resulting in a peak serum concentration of 0.05 µg/ml, the x223C;ED50 value for the SVV inoculum in cell culture. BV-araU administered orally twice daily at 0.1 mg/kg for 10 days starting 48 h after intratracheal SVVinfection prevented vesicular rash development and suppressed viremia. Effective therapy could be initiated 96 h after infection. Taken together, these results indicate that BV-araU is effective oral therapy at doses that achieve peak serum levels equivalent to the ED50 for SVV in cell culture. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
